Cardiovascular diseases are described as the leading cause of morbidity and mortality in
modern societies. Therefore, the importance of cardiovascular diseases prevention is widely …

CYP2C19 is one of the principal enzymes involved in the bioactivation of the antiplatelet
prodrug clopidogrel. A common loss‐of‐function allele, CYP2C19* 2 (c. 681G> A; …

Cytochrome P450 (CYP) 2C19 catalyzes the bioactivation of the antiplatelet prodrug
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …

Objectives: This multicenter pragmatic investigation assessed outcomes following clinical
implementation of CYP2C19 genotype–guided antiplatelet therapy after percutaneous …

Routine integration of genotype data into drug decision making could improve patient safety,
particularly if many relevant genetic variants can be assayed simultaneously before …

CYP2C19 genotype‐guided antiplatelet therapy following percutaneous coronary
intervention is increasingly implemented in clinical practice. However, challenges such as …

Current guidelines recommend dual antiplatelet therapy—a P2Y12 inhibitor (clopidogrel,
prasugrel, or ticagrelor) and aspirin—for patients undergoing percutaneous coronary …

In the field of pharmacogenetics, we currently have a few markers to guide physicians as to
the best course of therapy for patients. For the most part, these genetic variants are within a …

Dual antiplatelet therapy with a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and
aspirin remains the standard of care for all patients undergoing percutaneous coronary …

Background: CYP2C19 loss-of-function (LOF) alleles impair clopidogrel effectiveness after
percutaneous coronary intervention. The feasibility, sustainability, and clinical impact of …